Amylin Pharmaceuticals Inc.’s board dodged a dissident shareholder bullet three years ago, but the San Diego-based biotech is back in the crosshairs of billionaire investor and activist shareholder Carl Icahn, who again is seeking to nominate a new slate of…
If you read our post earlier this week (Top 5 Tips for Pitching BioWorld), you know what kind of news BioWorld Today covers. Here are five more helpful hints regarding how to work with us: translation
Bad Behavior has blocked 819 access attempts in the last 7 days.
Join the Conversation